Zynerba Pharmaceuticals, Inc. (ZYNE) insider have most recently took part in a trading activity. On Jan 2, 2018 Rapp Michael, 10% Owner bought 15,000 shares having total worth of $194,850 at the price of $12.99 per share, following the transaction a total of 1,469,115 shares owned by Rapp Michael. Before this latest buy, Rapp Michael purchased ZYNE at 1 other times during the past twelve months, for a total investment of $974,000 at an average of $9.74 per share.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 3 times by insiders. an employee of the company was the buyer in 3 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Zynerba Pharmaceuticals, Inc. (ZYNE) traded up 3.79% on Jan 2, 2018, hitting $13. 295,555 shares of the company’s stock traded hands. Zynerba Pharmaceuticals, Inc. has a 52 week low of $5.73 and a 52 week high of $25.19. The company’s market cap is $127 million.
Zynerba Pharmaceuticals, Inc. (ZYNE) last announced its earnings results on Nov 14, 2017. The company reported -0.63 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.59 by $0.04., compared to the consensus estimate of $0 million. During the same quarter in the previous year, the company posted -0.67 earnings per share.
|earnings per share||-0.63||-0.65||-0.64||-0.60||-0.70||-0.67||-0.70||-0.62||-0.44|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018